Early reports showed that targeting c-MYC in vitro with triplex-forming (TFOs) and liposomal phosphorothioate oligonucleotides (PTOs) inhibits ovarian cancer cell growth (77, 78). The gene discussed is MYC; the disease is ovarian carcinoma.